Literature DB >> 1665094

Assessing response to therapy of spinal metastases with gadolinium-enhanced MR imaging.

K Sugimura1, A Kajitani, H Okizuka, M Sugihara, M Mizutani, T Ishida.   

Abstract

The utility of gadolinium-enhanced magnetic resonance (MR) imaging in assessing the response of spinal metastases to therapy was evaluated. Fifteen patients (62 affected vertebral bodies) with spinal metastases were evaluated with gadopentetate dimeglumine-enhanced imaging before and after irradiation or chemotherapy. Signal intensities of the lesions and of adjacent normal vertebral bodies were compared. Before therapy, metastatic foci enhanced significantly more than did normal vertebral bodies. After therapy, the lesions were divided into 37 responding lesions (group 1) and 25 nonresponding lesions (group 2). In group 1, lesion enhancement diminished considerably and the patients with these lesions remained clinically asymptomatic for 2-6 months. In group 2, lesion enhancement did not diminish much, and the difference between the groups was significant. Gadolinium-enhanced MR imaging may thus be a useful method for assessing the effectiveness of therapy for spinal metastases.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1665094     DOI: 10.1002/jmri.1880010414

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  3 in total

1.  Follow-up CT and MR findings of osteoblastic spinal metastatic lesions after stereotactic radiotherapy.

Authors:  Yoon Joon Hwang
Journal:  Jpn J Radiol       Date:  2012-04-12       Impact factor: 2.374

Review 2.  Imaging response to systemic therapy for bone metastases.

Authors:  Tobias Bäuerle; Wolfhard Semmler
Journal:  Eur Radiol       Date:  2009-05-26       Impact factor: 5.315

Review 3.  Improving the interpretation of bone marrow imaging in cancer patients.

Authors:  L Ollivier; S Gerber; D Vanel; H Brisse; J Leclère
Journal:  Cancer Imaging       Date:  2006-12-20       Impact factor: 3.909

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.